Pharma juggernaut Merck (NYSE: MRK ) may seem like one of the safest plays in the health care space; after all, it's a Dow component and has been in existence for decades. That does not mean, however, that this is an entirely risk-free investment. In this video, health care analyst Max Macaluso runs down three risks that every Merck shareholder needs to consider.
For nearly 100 years, Merck's cutting-edge research has led to a number of medical breakthroughs. Today, however, this pharma stalwart is staring down a steep patent cliff and facing generic competition for its top-selling drug. or more detailed information, make sure you take a look at our�brand new premium research report�today. Our senior biotech analyst Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by�clicking here.
No comments:
Post a Comment